The photographer Daniel Arnold spent the month of May camped outside the New York City Clerk’s Office, documenting couples getting married in irreverent, wild, untraditional — and sometimes very traditional — ways.
NYS Entity Status
NYS Filing Date
OCTOBER 02, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - B & A CATERING CORP.
AROUND THE WEB
- The Look: Getting Married Where the Catering Is a Pretzel Vendor
By DANIEL ARNOLD, JOANNA NIKAS and EVE LYONS - Saturday Jun 10, 2017
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
- Five Sites of New York’s L.G.B.T. History
Monday Jun 19, 2017
Jacob Riis Park, a Manhattan church, the Bum Bum Bar and more. In 360 degrees, visit five sites that helped shape New York City’s L.G.B.T. community and its history.
- Pride 2017: New York’s L.G.B.T.Q. Story Began Well Before Stonewall
By LIAM STACK - Monday Jun 19, 2017
The gay bar’s 1969 patron-police battle, hailed as a starting point, actually followed many events in the city, now mapped in a sites project.
- The Look: New York City Parks in the Summer: Romance, Games and a Performance for a Dying Tree
By DANIEL ARNOLD, JOANNA NIKAS and EVE LYONS - Saturday Sep 2, 2017
Daniel Arnold spent the last two months photographing parks in all five boroughs. The experience showed him “a very different pulse of the city.”
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]